Neurological Surgery 脳神経外科42巻10号

2014年10月発行

--------------------

文献抄録　Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy／Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial) :a randomised controlled phase 2 trial.

著者： 荒川芳輝¹

所属機関： ¹京都大学脳神経外科

ページ範囲：P.985 - P.985